Abstract

IntroductionKnowledge of HIV status relies on accurate HIV testing, and is the first step towards access to HIV treatment and prevention programmes. Globally, HIV‐status unawareness represents a significant challenge for achieving zero new HIV infections and deaths. In order to enhance knowledge of HIV status, the World Health Organisation (WHO) recommends a testing strategy that includes the use of HIV‐specific antibody point‐of‐care tests (POCT). These POCTs do not detect acute HIV infection, the stage of disease when viral load is highest but HIV antibodies are undetectable. Complicating things further, in the presence of antiretroviral therapy (ART) for pre‐exposure prophylaxis (PrEP) or post‐exposure prophylaxis (PEP), other currently available testing technologies, such as viral load detection for diagnosis of acute HIV infection, may yield false‐negative results. In this scoping review, we evaluate the evidence and discuss alternative HIV testing algorithms that may mitigate diagnostic dilemmas in the setting of increased utilization of ART for immediate treatment and prevention of HIV infection.DiscussionMissed acute HIV infection prevents people living with HIV (PLHIV) from accessing early treatment, increases likelihood of onward transmission, and allows for inappropriate initiation or continuation of PrEP, which may result in HIV drug resistance. While immediate ART is recommended for all PLHIV, studies have shown that starting ART in the setting of acute HIV infection may result in a delayed or complete absence of development of HIV‐specific antibodies, posing a diagnostic challenge that is particularly pertinent to resource‐limited, high HIV burden settings where HIV‐antibody POCTs are standard of care. Similarly, ART used as PrEP or PEP may supress HIV RNA viral load, complicating current HIV testing algorithms in resource‐wealthy settings where viral detection is included. As rollout of PrEP continues, HIV testing algorithms may need to be modified.ConclusionsWith increasing use of PrEP and ART in acute infection we anticipate diagnostic challenges using currently available HIV testing strategies. Research and surveillance are needed to determine the most appropriate assays and optimal testing algorithms that are accurate, affordable and sustainable.

Highlights

  • | INTRODUCTIONIn the current era of immediate antiretroviral therapy (ART), and pre- or post-exposure prophylaxis, confidently diagnosing HIV is becoming increasingly complex

  • Knowledge of HIV status relies on accurate HIV testing, and is the first step towards access to HIV treatment and prevention programmes

  • In 2014, the Joint United Nations Programme on HIV and AIDS (UNAIDS) set the 90-90-90 targets, whereby 90% of people with HIV will know their status, 90% diagnosed will be on antiretroviral therapy (ART) and 90% on ART will be virally supressed by 2020 [11]

Read more

Summary

| INTRODUCTION

In the current era of immediate antiretroviral therapy (ART), and pre- or post-exposure prophylaxis, confidently diagnosing HIV is becoming increasingly complex. Individuals at high risk or presenting with symptoms suggestive of AHI should have further diagnostic tests in addition to HIV-antibody testing, such as nucleic acid amplification testing (NAAT) and/or HIV p24 gag viral core protein Most of these tests require venous blood sampling, sophisticated laboratory infrastructure and advanced personnel training, which are costly, time consuming and unavailable in many settings. This scoping review was originally based on an invited symposium entitled “Strategies for diagnosing and managing AHI in the context of PrEP and immediate ART” at the 22nd International AIDS conference, July 2018. We aim to consider the difficulties in confirming HIV status using current testing strategies, and the reported challenges in confirming HIV status among people receiving PrEP or PEP, or those starting immediate ART in AHI using currently approved test kits and testing algorithms

| DISCUSSION
Findings
| CONCLUSIONS
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call